Verified discoveries, trials, and approvals for this cancer type. Every story separates evidence strength, regulatory status, and guideline position.
In the randomized, open-label, phase 3 innovaTV 301 trial, tisotumab vedotin significantly extended both overall survival (11.5 months versus 9.5 months) and progression-free survival (4.2 months versus 2.9 months), compared…
Primary source cited
Last reviewed
A population-based analysis of national mortality data in England (2001-2024) found a substantial reduction in cervical cancer mortality among women aged 20-29 associated with high uptake of England's HPV vaccination…
Primary source cited
Last reviewed
In the randomized, open-label, phase 3 innovaTV 301 trial, tisotumab vedotin significantly extended both overall survival (11.5 months versus 9.5 months) and progression-free survival (4.2 months versus 2.9 months), compared…
Primary source cited
Last reviewed
A population-based analysis of national mortality data in England (2001-2024) found a substantial reduction in cervical cancer mortality among women aged 20-29 associated with high uptake of England's HPV vaccination…
Primary source cited
Last reviewed
Regulatory approval is separate from evidence certainty and from guideline position. Approval applies only to the exact indication stated in each jurisdiction record.
innovaTV 301/ENGOT-cx12/GOG-3057 trial results: tisotumab vedotin versus chemotherapy in recurrent or metastatic cervical cancer (Annals of Oncology). DOI 10.1016/j.annonc.2023.10.029.
Applies to the exact indication stated.
Cervical cancer mortality trends following HPV vaccination in England, 2001-24: an analysis of population-based mortality data (The Lancet). DOI 10.1016/S0140-6736(26)00918-9.
Applies to the exact indication stated.
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.